{"disease":{"id":"high-grade-neuroendocrine-neoplasms","name":"high grade neuroendocrine neoplasms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07080242","title":"Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT04412629","title":"Cabozantinib in High Grade Neuroendocrine Neoplasms","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT06926634","title":"Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Washington University School of Medicine","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}